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Among the biotargets interacting with vanadium is the calcium pump from the sarcoplasmic reticulum (SR). To this end, initial
research eﬀorts were launched with two vanadium(V)–citrate complexes, namely (NH4)6[V2O4(C6H4O7)2] Æ 6H2O and
(NH4)6[V2O2(O2)2(C6H4O7)2] Æ 4H2O, potentially capable of interacting with the SR calcium pump by combining kinetic studies with
51V NMR spectroscopy. Upon dissolution in the reaction medium (concentration range: 4–0.5 mM), both vanadium(V):citrate (VC)
and peroxovanadium(V):citrate (PVC) complexes are partially converted into vanadate oligomers. A 1 mM solution of the PVC com-
plex, containing 184 lM of the PVC complex, 94 lM oxoperoxovanadium(V) (PV) species, 222 lM monomeric (V1), 43 lM dimeric
(V2) and 53 lM tetrameric (V4) species, inhibits Ca2+ accumulation by 75 %, whereas a solution of the VC complex of the same vana-
dium concentration, containing 98 lM of the VC complex, 263 lM monomeric (V1), 64 lM dimeric (V2) and 92 lM tetrameric (V4)
species inhibits the calcium pump activity by 33 %. In contrast, a 1 mM metavanadate solution, containing 460 lM monomeric (V1),
90.2 lM dimeric (V2) and 80 lM tetrameric (V4) species, has no eﬀect on Ca2+ accumulation. The NMR signals from the VC complex
(548.0 ppm), PVC complex (551.5 ppm) and PV (611.1 ppm) are broadened upon SR vesicle addition (2.5 mg/ml total protein). The
relative order for the half width line broadening of the NMR signals, which reﬂect the interaction with the protein, was found to be
V4 > PVC > VC > PV > V2 = V1 = 1, with no eﬀect observed for the V1 and V2 signals. Putting it all together the eﬀects of two vana-
dium(V)–citrate complexes on the modulation of calcium accumulation and ATP hydrolysis by the SR calcium pump reﬂected the
observed variable reactivity into the nature of key species forming upon dissolution of the title complexes in the reaction media.
 2005 Elsevier Inc. All rights reserved.
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Almost 30 years after the discovery that vanadium was a
muscle inhibiting factor and a Na+/K+-ATPase inhibitor
present in commercially available ATP [1–3], it still remains
to be clariﬁed whether or not vanadium has a physiological0162-0134/$ - see front matter  2005 Elsevier Inc. All rights reserved.
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E-mail address: maalves@ualg.pt (M. Aureliano).role in the muscle. It is believed that the complex chemistry
of vanadium itself, its interactions with small molecules of
biological interest, and vanadate similarities with phos-
phate constitute the rudiments of research emerging from
the increased interest in vanadium in biological systems.
Among the eﬀects attributed to vanadium salts and com-
plexes, the insulin mimetic action stands prominent [4,5].
However, vanadium toxicity and poor absorption in the
gastrointestinal tract is still a major obstacle in the develop-
ment of therapeutic applications [6]. The challenge of
2356 M. Aureliano et al. / Journal of Inorganic Biochemistry 99 (2005) 2355–2361overcoming these obstacles has spurred considerable re-
search activity, targeting the interaction of vanadium with
biomolecules and organic ligands, in order to enhance
absorption and eﬃciency while concurrently reducing tox-
icity. To that end, a number of ligands, such as citric acid,
have been employed as potential ligand binders of vana-
dium in biological systems [7–9].
It is known that vanadium ions and vanadium com-
plexes inhibit or stimulate the activity of various enzymes.
In the case of the membrane bound E1–E2 Ca2+-ATPase
(calcium pump) from sarcoplasmic reticulum (SR), the
inhibition is promoted by orthovanadate binding to the
E2 conformation of the protein [10]. Moreover, the use
of vanadate is related to the catalytic site of Ca2+ ATPase,
which contains an aspartyl that is phosphorylated during
the catalytic cycle thereby forming an acyl phosphate anhy-
dride [11]. In addition to monomeric vanadate species, it
has been reported that other vanadate oligomers interact
with the SR calcium pump [12]. It has been demonstrated
that some of the interactions, e.g. decameric species, dis-
rupt the energy coupling and enzyme turnover. Other inter-
actions of vanadium, e.g. monomeric species, may have no
implicit eﬀect or even improve the coupling to the Ca2+
pump [13]. The SR calcium pump was reported to have a
decreased activity in some diabetic conditions, which could
result in impaired cardiac relaxation [14]. Several studies
have been carried out using vanadium(V) for characteriza-
tion of SR calcium pump [13,15]. Indeed, SR calcium pump
has proven to be an excellent model to study Ca2+ homeo-
stasis aﬀected by acute and cronic exposure of nitrosative
stress [16].
In the present study, the eﬀects of two vanadium(V)–
citrate complexes namely (NH4)6[V2O4(C6H4O7)2] Æ 6H2O
and (NH4)6[V2O2(O2)2(C6H4O7)2] Æ 4H2O, on the modula-
tion of calcium accumulation and ATP hydrolysis by the
SR calcium pump were evaluated. The results demon-
strated that it is of primary importance to precisely charac-
terize the aqueous behaviour of the vanadium(V) species
and their interactions with the investigated biosystem prior
to attempting to understand the promoted eﬀects. Both
vanadium(V)–citrate complexes interact and aﬀect the
activity of the SR calcium pump, with the peroxovana-
dium(V):citrate complex solutions being the most potent
inhibitor.
2. Materials and methods
2.1. Reagents
Chemicals used to prepare buﬀers were of reagent grade.
Ammonium metavanadate and citric acid were purchased
from Riedel-de Hae¨n. ATP (vanadium free) was supplied
by Sigma. All other reagents were of biochemical analysis
grade from BDH, Merck or Sigma.
The synthesis of the vanadium(V) complexes
(NH4)6[V2O4(C6H4O7)2] Æ 6H2O and (NH4)6[V2O2(O2)2
(C6H4O7)2] Æ 4H2O was achieved according to published lit-erature procedures [17,18]. In these articles, the character-
ization of the complexes was carried out with analytical,
spectroscopic techniques (UV–Visible, 13C NMR (in the
case of the ternary vanadium(V)–peroxo-citrate complex),
FT-IR) and X-ray crystallographic techniques. Therefore,
the structures of the two complexes are known along with
their chemical reactivity. The 51V NMR, however, is not
available for the two species and thus cannot be included
in this manuscript.
Vanadium–citrate complex stock solutions (9 mM) used
in the studies were prepared from vanadium(V)–citrate
(NH4)6[V2O4(C6H4O7)2] Æ 6H2O and from vanadium(V)–
peroxo-citrate (NH4)6[V2O2(O2)2(C6H4O7)2] Æ 4H2O salts
in a medium containing 25 mM Hepes (2-(4-(2-hydroxy-
ethyl)-1-piperazinyl)ethanesulphonic acid), pH 7.0, and
0.1 M KCl.
2.2. Preparation of sarcoplasmic reticulum vesicles
Sarcoplasmic reticulum vesicles (SRV) were prepared
from white skeletal rabbit muscles as described elsewhere
[13]. Isolated SRV suspended in KCl 0.1 M, tris(hydroxy-
methyl)aminometane (Tris) 10 mM (pH 7.0) were diluted
1:1 with sucrose 2 M and frozen in liquid nitrogen prior
to storage at 80 C. For SRV preparations used in
NMR studies, no sucrose was added, once sucrose forms
complexes with vanadium and in the 51V NMR appears
two signals at 540 and 550 ppm as described previously
[13]. Protein concentration was determined by the biuret
method, using bovine serum albumin as a standard [19].
The percentage of each protein present in the SRV prepa-
rations was determined trough densitometry analysis of
sodium dodecyl sulphate (SDS)–polyacrylamide gel
electrophoresis (7.5% acrylamide). The SR Ca2+-ATPase
analysed by SDS–polyacrylamide gel electrophoresis was
at least 70% of the total protein in SRV.2.3. NMR measurements
51V Nuclear magnetic resonance spectroscopy measure-
ments on vanadium(V)–citrate complex solutions were ta-
ken on a Bruker AM-400 MHz, by using a 90 pulse
Fourier transform technique. Chemical shift values are gi-
ven with reference to VOCl3 (0 ppm) as a standard. The rel-
ative areas of several free and bound vanadate resonances
were integrated and the line widths were obtained by sub-
tracting the value (20 Hz) used in line broadening. The con-
centrations of vanadate oligomers Vx were calculated from
the fractions of the total integrated areas observed in the
recorded spectra as described in the equation below. The
symbol A corresponds to the area measured for the x vana-
dium(V) species (Vx) with n being the aggregation number
(number of vanadium atoms), A(Vt), the sum of the mea-
sured area and [Vt] the total vanadium(V) concentration
½Vx ¼ AðVxÞ  1AðVtÞ 
½Vt
nðVxÞ .
Fig. 1. 105.2 MHz 51V NMR spectra, at 22 C, of a 9 mM vanadium(V)–
citrate complex solution prepared in water (a) or in the reaction medium
(b). VC and V4 stands for vanadium(V)–citrate and tetrameric vanadate
species, respectively.
Fig. 2. 105.2 MHz 51V NMR spectra, at 22 C, of diﬀerent concentra-
tions, namely 0.5 mM (a); 1 mM (b); 2 mM (c); 4 mM (d) and 9 mM (e)
total vanadium, of a vanadium(V)–citrate (VC) complex in a medium
containing 25 mM Hepes, pH 7.0, and 0.1 M KCl. V1 and V2 NMR
signals correspond, respectively, to monomeric ðH2VO4 Þ and dimeric
ðHV2O37 and H2V2O27 Þ vanadate species irrespective of the protonation
state, whereas V4 and V5 correspond to cyclic tetrameric ðV4O412 Þ and
pentameric ðV5O515 Þ vanadate species.
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and PVC complexes) were obtained at several concentra-
tions in the reaction medium, containing KCl 0.1 M,
MgCl2 5 mM, Hepes 25 mM (pH 7.0), CaCl2 50 lM and
ATP 500 lM in Hepes 25 mM (pH 7.0). Spectra of 2 mM
vanadium(V)–citrate complex solutions were also obtained
in the same reaction medium, in the absence and presence
of 2.5 mg/ml of SR preparations. The spectra were ac-
quired at room temperature, spectral with 40,355 Hz, accu-
mulation time 0.05 s, number of transients between 12,000
and 25,000 and relaxation delay 0.01 s. For quantitative
measurements all of the spectral parameters were kept con-
stant [12].
2.4. ATP hydrolysis by calcium pump
ATP hydrolysis was measured by colorimetric determi-
nation of inorganic phosphate [20]. Kinetic experiments
were performed at 25 C in a reaction medium containing
KCl 0.1 M, Hepes 25 mM (pH 7.0), MgCl2 5 mM, CaCl2
50 lM, 0.285 g/ml of SRV preparations, in the absence
or presence of 1 mM vanadate, vanadium(V) complexes
or citrate, according to the required experimental condi-
tions. Vanadate, vanadium–citrate complexes or citrate
solutions were added to the medium prior to protein addi-
tion. The reaction was initiated by adding Mg-ATP
500 lM and was subsequently monitored for up to 20 min.
2.5. Ca2+ uptake experiments
Ca2+ uptake experiments were performed as described
elsewhere [12]. The experiments were carried out at 25 C
in a 4 ml assay medium, containing KCl 0.1 M, MgCl2
5 mM, Hepes 25 mM (pH 7.0), CaCl2 20 lM, and
0.1 mg/ml SR preparations. The reaction was initiated by
adding ATP 500 lM in Hepes 25 mM (pH 7.0). At the
end of each experiment, an internal calibration was per-
formed by addition of standard CaCl2 solutions. Vana-
dium(V)–citrate complex or metavanadate solutions at
several concentrations were added to the medium prior to
ATP addition.
3. Results and discussion
3.1. Spectroscopic characterization of the complexes
The 51V NMR spectra of 9 mM solutions of the vana-
dium(V):citrate complex (VC) in water (pH 6.6) exhibit res-
onances at 546 and at 549 ppm (Fig. 1). The relative
areas of the resonances reﬂect a 1:1 ratio, with the half line
width of these signals being very similar (180 ± 10 Hz).
When the VC complex solution was prepared in the reac-
tion medium, another NMR signal was detected at
578 ppm. Upon dissolution, of the VC complex, in the
reaction medium at lower concentrations (from 4 to
0.5 mM), the VC complex is partially converted into vana-
date oligomers (Fig. 2). NMR signals ascribed to mono(V1) at 561 ppm, dimeric (V2) at 574 ppm and
tetrameric (V4) at 578 ppm vanadate species were
observed, whereas the VC NMR resonance at 546 ppm
Fig. 4. 105.2 MHz 51V NMR spectra, at 22 C, of diﬀerent concentrations
of a peroxovanadium(V)–citrate (PVC) complex in a medium containing
25 mM Hepes, pH 7.0, and 0.1 M KCl: 0.5 mM (a); 1 mM (b); 2 mM (c);
4 mM (d) and 9 mM (e) total vanadium. V1 and V2 NMR signals
correspond, respectively, to monomeric ðH2VO4 Þ and dimeric ðHV2O37
and H2V2O
2
7 Þ vanadate species irrespective of the protonation state,
whereas V4 correspond to cyclic tetrameric ðV4O412 Þ vanadate species.
PVC1 and PVC2 stands for peroxovanadium(V)–citrate species, while PV
stands for oxoperoxovanadium(V) species.
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tal vanadium (Fig. 2).
Three NMR signals are observed for the peroxovana-
dium(V):citrate (PVC) complex dissolved in water (pH
4.4) or in the reaction medium (9 mM total vanadium).
The signals appear at 542 ppm (PVC1), 551 ppm
(PVC2) and 609 ppm (PV), with the half line widths of
these signals being about 200, 150 and 100 Hz, respectively
(Fig. 3). The relative areas show a ﬁrst signal twice as large
as the second, probably reﬂecting conformers of the same
complex. The NMR signal observed at 609 ppm (PV,
Fig. 3) is due to an oxoperoxovanadium(V) species, indi-
cating that the PVC complex dissociates as well. Further-
more, upon dissolution of the PVC complex in the
reaction medium, at lower concentrations (from 4 to
0.5 mM), it is partially converted into vanadate oligomers
(Fig. 4), a behaviour that was also observed above for
VC complex. The two complexes as discrete chemical spe-
cies possess their own chemical properties reﬂected in un-
ique pattern of degradation. To this end, the PVC
complex appears to be more stable toward ultimate vana-
date oligomer degradation than the VC complex. That
can be easily attested by 51V NMR, showing that the van-
adate oligomers signals are solely and clearly observed for
concentrations ½VVtotal 6 1 mM (Fig. 4). In fact, the species
composition of the VC and PVC complex solutions varies
with the total vanadium concentration (Fig. 5). At vana-
dium concentrations up to 2 mM, diﬀerent species occur
simultaneously for both the VC and PVC complexes,
whereas at higher vanadium(V) concentrations the VC
and PVC complexes are favoured. Even for solutions
9 mM in total vanadium, only about 4.2 and 3.6 mM of
VC and PVC complexes are present, respectively (Fig. 5).
Therefore, it was diﬃcult to obtain a solution containing
exclusively a single vanadium(V) species, and even when
that was achieved, other species appeared when the solu-
tion was diluted in the reaction medium. Consequently,Fig. 3. 105.2 MHz 51V NMR spectra, at 22 C, of a 9 mM peroxovana-
dium(V)–citrate complex solution prepared in water (a) or in the reaction
medium (b). PVC1 and PVC2 stands for peroxovanadium(V)–citrate
species, while PV stands for oxoperoxovanadium(V) species.in order to investigate the interactions and eﬀects of the
complexes with the SR calcium pump, higher concentra-
tions were used.
3.2. 51V NMR study on the interaction of the complexes with
SR calcium pump
Upon addition of sarcoplasmic reticulum vesicles (SRV,
2.5 mg/ml of total protein) to the VC complex solution
(2 mM total vanadium) prepared in the reaction medium,
the 51V NMR signal at 548 ppm broadens (from 506 to
657 Hz) and its intensity decreases (Fig. 6(a)). This solu-
tion, however, contains vanadate oligomers, with the tetra-
meric vanadate signal resonance sustaining an enormous
decrease in intensity upon SRV addition. In contrast, as
it was observed by 51V NMR, the PVC complex solution
(2 mM total vanadium) prepared in the reaction medium
does not contain vanadate oligomers and thus the interac-
tions with the SR calcium pump can only be related to the


















































Fig. 5. Vanadium(V) species composition of vanadium(V)–citrate (a) and
peroxovanadium(V)–citrate (b) solutions used in the assays. A series of
51V NMR spectra of vanadium(V)–citrate and peroxovanadium(V)–
citrate solutions were recorded at concentrations up to 9 mM, in a
medium containing 25 mM Hepes, pH 7.0, 0.1 M KCl, at 22 C. The
concentrations of each vanadium(V) species were calculated from the
fractions of the total integrated areas observed in the spectra.
Fig. 6. 105.2 MHz 51V NMR spectra of 2 mM vanadium(V)–citrate
complex (a) or peroxovanadium(V)–citrate (b) in a medium containing
25 mM Hepes, pH 7.0, 0.1 M KCl, 5 mM MgCl2, in the absence (SRV)
or in the presence (+SRV) of sarcoplasmic reticulum vesicles (2.5 mg/ml
total protein).
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signals detected at 542 and 609 ppm, ascribed to the
PVC complex and to PV, broadened from 175 to 281 Hz
and from 93 to 112 Hz, respectively, and decreased in
intensity in the presence of the calcium pump (Fig. 6(b)).
Putting all together, the relative order of the half width line
broadening for the NMR signals, which reﬂect the interac-
tion of the complexes with protein, was V4 > PVC >
VC > PV > V2 = V1 = 1, with no eﬀects observed for the
V1 and V2 signals. Moreover, upon phosphorylation by
Pi or ATP following the methodology described elsewhere
[12], the diﬀerent forms E2 and E1 of the enzyme did not
aﬀect the NMR signals of the complexes observed follow-
ing SRV addition (not shown).
Early 51V NMR studies on the binding of various ionic
forms of vanadate to SRV have clearly shown that the
NMR resonances for the free oligomeric species of vana-date, present at pH 7.4, decrease upon addition of the pro-
tein [21]. More recently, it was demonstrated that the
changes in the NMR spectra are caused by alterations in
the Ca2+-ATPase induced by ATP [12]. These authors de-
scribed that the signals for tetrameric vanadate increase in
intensity and become narrower, whereas the signal for
monomeric vanadate become broader, suggesting that
ATP increases the aﬃnity of monomeric species for the en-
zyme but decreases the aﬃnity for the tetrameric species. In
studies with myosin, similar ﬁndings were reported for tet-
rameric and monomeric species following ATP addition
[22].
Diﬀerent SR ATPase conformational forms arisen from
the presence of speciﬁc ligands can be ascribed to vana-
dium(V) aﬃnities for the protein. Our data indicate that
the aﬃnity of both vanadium(V) complexes is not appar-
ently aﬀected when the diﬀerent forms E2 and E1 of the en-
zyme are induced. Moreover, the aﬃnity for both forms of
the ATPase does not change upon phosphorylation by Pi
or ATP. It has been suggested that ’’monovanadate’’ spe-
cies may bind to the ATPase in the vicinity of the aspartyl
phosphate acceptor, resulting in the blockage of the active
site by avoiding phosphoenzyme intermediate formation,
whereas the decavanadate binding site to the enzyme has
been reported to be very close to the ATP binding site
[13,15]. In the present work, it is suggested that the vana-
dium(V) complexes may modulate the calcium pump
through a diﬀerent interaction than the one observed for
vanadate oligomers. This indicates that the complexity of
vanadium eﬀects is not only due to the presence of diﬀerent
oligomers in solution, which were shown to promote diﬀer-
ent in vivo eﬀects [23], but also to the inﬂuence of potential
ligand binders of vanadium in biological systems.
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by VC and PVC complexes
The inhibition promoted on the SR calcium pump ATP
hydrolysis process was similar for both VC and PVC com-
plex solutions, with a 50% inhibition at 0.5 mM (Fig. 7).
However, with respect to Ca2+ accumulation by the SR cal-
cium pump, the PVC complex solution exerted a stronger
inhibition on this process, with an IC50 value of 1.1 mM
(Fig. 7(b)), compared to a 2.0 mMIC50value for theVCcom-
plex solutionpromoting the same eﬀect (Fig. 7(a)).Under the
same experimental conditions, it was observed that meta-
vanadate does not aﬀect Ca2+ accumulation by the calcium
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Fig. 7. Eﬀects of the vanadium(V)–citrate complex (a) and peroxo
vanadium(V)–citrate complex (b) solutions, on phosphate production
during ATP splitting (dashed line, open squares) and Ca2+ accumulation
(solid line, solid squares) by the SR calcium pump. The reactions were
monitored at 25 C, in an assay medium containing 0.1 M KCl, 5 mM
MgCl2, 50 lM CaCl2, 285 lg/ml protein or 100 lg/ml (according to
Section 2) and 25 mM Hepes, pH 7.0. The reactions were started upon
addition of 500 lMMgATP and were monitored for 10 min. The provided
rates reﬂect the means of at least six independent experiments.tion of the PVC complex inhibits the Ca2+ accumulation by
75 %, whereas a solution of the VC complex of the same
vanadium concentration inhibits the calcium pump activity
by 33 %, meaning that the IC50 value obtained for the latter
complex is eventually lower than the obtained through the
function that ﬁts the graph. Even so, if we considered the ob-
tained IC50 values, theCa
2+/ATP stoichiometrywas aﬀected
diﬀerently by both complex solutions: the VC complex in-
duced an increase in pump eﬃciency (thereby increasing
Ca2+/ATP ratio), whereas the PVC complex did not aﬀect
Ca2+/ATP stoichiometry. For the former complex the eﬀects
may not be exclusively attributed to it, without deﬁne the
inﬂuence of the PV species on the inhibition of ATPase
hydrolysis and Ca2+ accumulation.
In order to evaluate the eﬀect of citrate alone, a struc-
tural component of these vanadium(V)–citrate complex
solutions, on the inhibition registered by VC and PVC
complexes, the ATP hydrolysis and Ca2+ accumulation
processes were measured in the presence of several citrate
concentrations. It was observed that citrate induced an in-
crease in sarcoplasmic reticulum Ca2+ accumulation, with
no discernible eﬀect on the hydrolytic activity (not shown).
In fact, Ca2+ accumulation increased by 23% and 70 % in
the presence of 2 and 4 mM citrate, respectively. This eﬀect
may explain the increase in Ca2+/ATP ratio observed for
the VC complex (Fig. 7(a)). In contrast, citrate did not af-
fect the inhibition by the PVC complex, even though it was
veriﬁed that the complex dissociates, giving rise to oligo-
mers and also to oxoperoxovanadium(V) and therefore
inducing, to a lower extent than the VC complex, the
appearance of citrate.
4. Concluding remarks
51V NMR spectroscopy was used to determine the com-
position of the VC and PVC complex solutions in the reac-
tion medium and then to calculate the concentrations of
the various species present in solution relative to the total
vanadium concentration. In the concentration range used,
it was observed that the vanadium(V) complex solutions
contain, besides vanadium(V) complexes and oxoperox-
ovanadium(V) species, diﬀerent amounts of mono (V1);
di (V2); tetra (V4) and pentameric (V5) species (Fig. 6).
NMR spectra of a 1 mM VC complex solutions in the reac-
tion medium indicated that the solutions contain 98 lM of
complex, 263 lM monomeric (V1), 64 lM dimeric (V2)
and 92 lM tetrameric (V4) species, whereas a 1 mM PVC
complex solutions contain 184 lM of complex, 94 lM oxo-
peroxovanadium(V) species, 222 lM monomeric (V1),
43 lM dimeric (V2) and 53 lM tetrameric (V4) species. It
should be noted that a 1 mM of metavanadate solution
contains, under the same experimental conditions, about
460 lM monomeric, 90 lM dimeric and 80 lM tetrameric
vanadate species. The unique nature of the title complexes
investigated and their emerging patterns of degradation in
aqueous media dictate a commensurately unique biological
activity exerted in the presence of the biological target (the
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concentrations, inhibit Ca2+ accumulation to variable de-
grees, namely 75%, 33% and 2% for PVC, VC and meta-
vanadate solutions, respectively. These results point out
an interesting behaviour of the vanadate complexes. Specif-
ically, based on total vanadium concentration of vanadium
present in the ternary PVC and binary VC complex solu-
tions of the same 1 mM concentration, the PVC complex
is more potent (2.3 times higher) than the VC complex.
Thus, the peroxovanadate complex appears to be a more
potent inhibitor of the calcium pump.
It is considered to be of primary importance to precisely
characterize the vanadium species that could interact with
an enzyme system prior to attempting to investigate any ef-
fects promoted by vanadium(V)-containing solutions. To
that end, it was not possible to clearly deﬁne the eﬀects pro-
moted by each individual vanadium(V)–citrate complex.
Concomitantly, due to the complexity of the system, which
contains several vanadium(V) species interacting with mul-
tiple sites on the Ca2+-ATPase, that can adopt several con-
formations, it was not possible to completely deﬁne the
eﬀects of the vanadium(V):citrate species on sarcoplasmic
reticulum Ca2+-ATPase activity. It was clear, however,
that enzyme activity inhibition increases in the presence
of the title complexes, suggesting an interaction of vana-
dium with the sarcoplasmic reticulum Ca2+-ATPase diﬀer-
ent from that exhibited by other vanadate oligomers.
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